148 related articles for article (PubMed ID: 30140035)
1. The combination of PTEN deletion and 16p13.3 gain in prostate cancer provides additional prognostic information in patients treated with radical prostatectomy.
Bramhecha YM; Rouzbeh S; Guérard KP; Scarlata E; Brimo F; Chevalier S; Hamel L; Aprikian AG; Lapointe J
Mod Pathol; 2019 Jan; 32(1):128-138. PubMed ID: 30140035
[TBL] [Abstract][Full Text] [Related]
2. A multicenter study shows PTEN deletion is strongly associated with seminal vesicle involvement and extracapsular extension in localized prostate cancer.
Troyer DA; Jamaspishvili T; Wei W; Feng Z; Good J; Hawley S; Fazli L; McKenney JK; Simko J; Hurtado-Coll A; Carroll PR; Gleave M; Lance R; Lin DW; Nelson PS; Thompson IM; True LD; Brooks JD; Squire JA
Prostate; 2015 Aug; 75(11):1206-15. PubMed ID: 25939393
[TBL] [Abstract][Full Text] [Related]
3. Association of ERG/PTEN status with biochemical recurrence after radical prostatectomy for clinically localized prostate cancer.
Mehra R; Salami SS; Lonigro R; Bhalla R; Siddiqui J; Cao X; Spratt DE; Palapattu GS; Palanisamy N; Wei JT; Chinnaiyan AM; Tomlins SA
Med Oncol; 2018 Oct; 35(12):152. PubMed ID: 30291535
[TBL] [Abstract][Full Text] [Related]
4. Integrated analysis of the genomic instability of PTEN in clinically insignificant and significant prostate cancer.
Murphy SJ; Karnes RJ; Kosari F; Castellar BE; Kipp BR; Johnson SH; Terra S; Harris FR; Halling GC; Klein JL; Nasir A; Bergstrahl E; Rangel LJ; Sukov WR; Vasmatzis G; Cheville JC
Mod Pathol; 2016 Feb; 29(2):143-56. PubMed ID: 26612463
[TBL] [Abstract][Full Text] [Related]
5. Genomic Gain of 16p13.3 in Prostate Cancer Predicts Poor Clinical Outcome after Surgical Intervention.
Bramhecha YM; Guérard KP; Rouzbeh S; Scarlata E; Brimo F; Chevalier S; Hamel L; Dragomir A; Aprikian AG; Lapointe J
Mol Cancer Res; 2018 Jan; 16(1):115-123. PubMed ID: 28993510
[TBL] [Abstract][Full Text] [Related]
6. Deletion of 8p is an independent prognostic parameter in prostate cancer.
Kluth M; Amschler NN; Galal R; Möller-Koop C; Barrow P; Tsourlakis MC; Jacobsen F; Hinsch A; Wittmer C; Steurer S; Krech T; Büscheck F; Clauditz TS; Beyer B; Wilczak W; Graefen M; Huland H; Minner S; Schlomm T; Sauter G; Simon R
Oncotarget; 2017 Jan; 8(1):379-392. PubMed ID: 27880722
[TBL] [Abstract][Full Text] [Related]
7. High nuclear karyopherin α 2 expression is a strong and independent predictor of biochemical recurrence in prostate cancer patients treated by radical prostatectomy.
Grupp K; Habermann M; Sirma H; Simon R; Steurer S; Hube-Magg C; Prien K; Burkhardt L; Jedrzejewska K; Salomon G; Heinzer H; Wilczak W; Kluth M; Izbicki JR; Sauter G; Minner S; Schlomm T; Tsourlakis MC
Mod Pathol; 2014 Jan; 27(1):96-106. PubMed ID: 23887301
[TBL] [Abstract][Full Text] [Related]
8. Comparing Prognostic Utility of a Single-marker Immunohistochemistry Approach with Commercial Gene Expression Profiling Following Radical Prostatectomy.
Leapman MS; Nguyen HG; Cowan JE; Xue L; Stohr B; Simko J; Cooperberg MR; Carroll PR
Eur Urol; 2018 Nov; 74(5):668-675. PubMed ID: 30181067
[TBL] [Abstract][Full Text] [Related]
9. Loss of PTEN expression in ERG-negative prostate cancer predicts secondary therapies and leads to shorter disease-specific survival time after radical prostatectomy.
Lahdensuo K; Erickson A; Saarinen I; Seikkula H; Lundin J; Lundin M; Nordling S; Bützow A; Vasarainen H; Boström PJ; Taimen P; Rannikko A; Mirtti T
Mod Pathol; 2016 Dec; 29(12):1565-1574. PubMed ID: 27562498
[TBL] [Abstract][Full Text] [Related]
10. Identification of Combinatorial Genomic Abnormalities Associated with Prostate Cancer Early Recurrence.
Qu X; Jeldres C; Glaskova L; Friedman C; Schroeder S; Nelson PS; Porter C; Fang M
J Mol Diagn; 2016 Mar; 18(2):215-24. PubMed ID: 26752304
[TBL] [Abstract][Full Text] [Related]
11. Loss of PTEN Expression Detected by Fluorescence Immunohistochemistry Predicts Lethal Prostate Cancer in Men Treated with Prostatectomy.
Hamid AA; Gray KP; Huang Y; Bowden M; Pomerantz M; Loda M; Sweeney CJ
Eur Urol Oncol; 2019 Sep; 2(5):475-482. PubMed ID: 31411988
[TBL] [Abstract][Full Text] [Related]
12. βIII-tubulin overexpression is an independent predictor of prostate cancer progression tightly linked to ERG fusion status and PTEN deletion.
Tsourlakis MC; Weigand P; Grupp K; Kluth M; Steurer S; Schlomm T; Graefen M; Huland H; Salomon G; Steuber T; Wilczak W; Sirma H; Simon R; Sauter G; Minner S; Quaas A
Am J Pathol; 2014 Mar; 184(3):609-17. PubMed ID: 24378408
[TBL] [Abstract][Full Text] [Related]
13. Copy number alterations of c-MYC and PTEN are prognostic factors for relapse after prostate cancer radiotherapy.
Zafarana G; Ishkanian AS; Malloff CA; Locke JA; Sykes J; Thoms J; Lam WL; Squire JA; Yoshimoto M; Ramnarine VR; Meng A; Ahmed O; Jurisica I; Milosevic M; Pintilie M; van der Kwast T; Bristow RG
Cancer; 2012 Aug; 118(16):4053-62. PubMed ID: 22281794
[TBL] [Abstract][Full Text] [Related]
14. SPINK1 Overexpression in Localized Prostate Cancer: a Rare Event Inversely Associated with ERG Expression and Exclusive of Homozygous PTEN Deletion.
Huang KC; Evans A; Donnelly B; Bismar TA
Pathol Oncol Res; 2017 Apr; 23(2):399-407. PubMed ID: 27738792
[TBL] [Abstract][Full Text] [Related]
15. Combined value of validated clinical and genomic risk stratification tools for predicting prostate cancer mortality in a high-risk prostatectomy cohort.
Cooperberg MR; Davicioni E; Crisan A; Jenkins RB; Ghadessi M; Karnes RJ
Eur Urol; 2015 Feb; 67(2):326-33. PubMed ID: 24998118
[TBL] [Abstract][Full Text] [Related]
16. PTEN loss and chromosome 8 alterations in Gleason grade 3 prostate cancer cores predicts the presence of un-sampled grade 4 tumor: implications for active surveillance.
Trock BJ; Fedor H; Gurel B; Jenkins RB; Knudsen BS; Fine SW; Said JW; Carter HB; Lotan TL; De Marzo AM
Mod Pathol; 2016 Jul; 29(7):764-71. PubMed ID: 27080984
[TBL] [Abstract][Full Text] [Related]
17. PTEN loss is associated with upgrading of prostate cancer from biopsy to radical prostatectomy.
Lotan TL; Carvalho FL; Peskoe SB; Hicks JL; Good J; Fedor H; Humphreys E; Han M; Platz EA; Squire JA; De Marzo AM; Berman DM
Mod Pathol; 2015 Jan; 28(1):128-137. PubMed ID: 24993522
[TBL] [Abstract][Full Text] [Related]
18. PTEN Loss in Gleason Score 3 + 4 = 7 Prostate Biopsies is Associated with Nonorgan Confined Disease at Radical Prostatectomy.
Guedes LB; Tosoian JJ; Hicks J; Ross AE; Lotan TL
J Urol; 2017 Apr; 197(4):1054-1059. PubMed ID: 27693448
[TBL] [Abstract][Full Text] [Related]
19. Absence of TMPRSS2:ERG fusions and PTEN losses in prostate cancer is associated with a favorable outcome.
Yoshimoto M; Joshua AM; Cunha IW; Coudry RA; Fonseca FP; Ludkovski O; Zielenska M; Soares FA; Squire JA
Mod Pathol; 2008 Dec; 21(12):1451-60. PubMed ID: 18500259
[TBL] [Abstract][Full Text] [Related]
20. The Combination of DNA Ploidy Status and PTEN/6q15 Deletions Provides Strong and Independent Prognostic Information in Prostate Cancer.
Lennartz M; Minner S; Brasch S; Wittmann H; Paterna L; Angermeier K; Öztürk E; Shihada R; Ruge M; Kluth M; Koop C; Wilczak W; Krech T; Lebok P; Wittmer C; Heinzer H; Steuber T; Adam M; Huland H; Graefen M; Haese A; Simon R; Sauter G; Schlomm T
Clin Cancer Res; 2016 Jun; 22(11):2802-11. PubMed ID: 26813356
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
